title: A new indication of botulinum toxin: leiomyoma-related pain.
abstract: Cutaneous leiomyomas are benign neoplasms with smooth muscle differentiation. They are painful tumors of the skin. Nearly 90% of patients report lesion-associated pain, characteristically precipitated by cold or trauma. In the published literature, surgical excision and pharmacologic agents such as analgesics, nifedipine, phenoxybenzamine hydrochloride, gabapentin, and doxazosin have been used in the treatment of leiomyomas with varying degrees of success. Herein we report the use of botulinum toxin for the relief of pain in leiomyomas. The use of botulinum toxin provided a decrease in the amount of analgesic use in our patient. Our experience showed that botulinum toxin might offer a new therapeutic approach for leiomyoma by reducing the intensity and the frequency of the pain. Botulinum toxin has no known systemic adverse effects, and can be combined with other treatments without concern for drug interactions. Like any other medication, aside from its actual pharmacologic effect, botulinum toxin may have had a placebo effect in our patient.
authors.affiliation: Department of Dermatology, Faculty of Medicine, Gazi University, Ankara, Turkey.
authors.forename: Meltem
authors.initials: M
authors.lastname: Onder
authors.forename: Esra
authors.initials: E
authors.lastname: Adişen
mesh_terms: D000328:Adult; D000700:Analgesics / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D018231:Leiomyomatosis / Q000150:complications*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology*; D017288:Pain Threshold / Q000187:drug effects; D012878:Skin Neoplasms / Q000150:complications*
chemical_list: D000700:Analgesics; D001905:Botulinum Toxins